Lorvas Tablet contains Indapamide 2.5 mg, a thiazide-like diuretic primarily indicated for the management of hypertension and edema associated with congestive heart failure, hepatic cirrhosis, or renal disorders. Indapamide acts on the distal convoluted tubules in the kidneys, promoting sodium and chloride excretion, which leads to increased urine output and reduction of extracellular fluid volume. This mechanism helps lower blood pressure by decreasing peripheral vascular resistance and reducing cardiac workload. Lorvas is effective in controlling high blood pressure, thereby reducing the risk of stroke, myocardial infarction, and other cardiovascular complications. The tablet is typically administered once daily, with dosage adjustments based on clinical response and patient tolerance. Common side effects may include electrolyte imbalances such as hypokalemia, hyponatremia, and hypercalcemia, as well as dizziness, headache, and gastrointestinal disturbances. Regular monitoring of serum electrolytes, renal function, and blood pressure is recommended during therapy to ensure safety and efficacy. Lorvas should be used cautiously in patients with renal or hepatic impairment and is contraindicated in cases of hypersensitivity to sulfonamides or severe electrolyte depletion. It is essential to follow the prescribing physician’s instructions and avoid abrupt discontinuation to maintain optimal therapeutic outcomes.